## Why "Perform sickle cell screening and avoid carbonic anhydrase inhibitors if positive" is right The clinical anchor emphasizes that spontaneous or disproportionate hyphema in patients of African descent mandates sickle cell screening, as sickled RBCs clog the trabecular meshwork and cause severe IOP spikes even with small-to-moderate hyphemas (this patient has Grade II hyphema at 40% AC). Critically, carbonic anhydrase inhibitors like acetazolamide are contraindicated in sickle cell disease because they cause metabolic acidosis, which worsens RBC sickling and paradoxically elevates IOP further. This is a life-changing decision point: if the patient is sickle-positive, the entire IOP management strategy must shift away from acetazolamide. The anchor text explicitly states: "SICKLE CELL SCREEN in all African-descent patients (sickled RBCs clog trabecular meshwork → severe IOP spikes even with small hyphemas; also AVOID CARBONIC ANHYDRASE INHIBITORS like acetazolamide which cause acidosis worsening sickling)." This screening and contraindication awareness is the most critical next step because it prevents iatrogenic harm and guides all subsequent therapy. ## Why each distractor is wrong - **Instill topical miotics (pilocarpine 2%) to reduce aqueous production and lower IOP**: Miotics are explicitly contraindicated in hyphema with inflammation because they can increase inflammation and promote posterior synechiae formation. The anchor states "AVOID miotics + prostaglandins in inflammation." Miotics do not reduce aqueous production meaningfully; they increase uveoscleral outflow but are harmful in this context. - **Apply a pressure patch and strict bed rest for 7 days with head elevation**: While bed rest with head elevation at 30° is correct management, a pressure patch is explicitly contraindicated. The anchor states "EYE SHIELD (no patch — patch can mask worsening)." A patch prevents monitoring of the eye and can hide signs of re-bleeding or corneal staining, making it dangerous. - **Initiate oral acetazolamide 500 mg twice daily along with topical timolol**: This is a trap answer for students who know acetazolamide lowers IOP in general glaucoma but miss the sickle cell contraindication. In an African-descent patient with hyphema, acetazolamide is absolutely contraindicated because it causes acidosis that worsens sickling. The correct agents are topical beta-blockers (timolol), alpha-2 agonists, and prostaglandins — but NOT acetazolamide in this population. **High-Yield:** In hyphema with African descent, always screen for sickle cell disease first — if positive, avoid acetazolamide entirely; use topical beta-blockers, alpha-2 agonists, and prostaglandins instead. [cite: AK Khurana Ophthalmology 7e — Hyphema section on sickle cell disease screening and management]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.